Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 28, 2024

Examining Trial Data on Omaveloxolone Efficacy

A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.

Episodes in this series

This series features 1 kol.

EP. 1 Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

This series features 1 kol.

EP. 2 Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

This series features 1 kol.

EP. 3 Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

This series features 1 kol.

EP. 4 Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

This series features 1 kol.

EP. 5 Examining Trial Data on Omaveloxolone Efficacy

This series features 1 kol.

EP. 6 Promising Therapy Approaches for Advanced Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 7 Friedreich Ataxia: Looking Forward at the Treatment Landscape

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 8 Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 9 Diagnosis of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 10 Impact of Friedreich Ataxia on Quality of Life

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 11 Clinical Utility of the Modified Friedreich Ataxia Rating Scale

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 12 Comorbidities and Complications Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 13 Challenges Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 14 Future Considerations for Friedreich Ataxia

In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

Stem Cell Transplant Outperforms DMTs in Drug-Resistant Relapsing MS

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

Health Equity & Access Weekly Roundup: July 17, 2026